COVID-19 Action

Websites and Documents

SBDC COVID-19

The OCIE SBDC wants to ensure that you and your business remain successful despite the vastly changing concerns about coronavirus (COVID-19). Visit this site for a look at the many resources we have provided or call 1-800-616-7232 for more information.

Visit
SBDC COVID-19 Resource Guide

News and resources for your business including information on disaster loans, business interruption insurance and other small business COVID-19 topics.

Download
ACA Small Business Owner's Guide to the CARES Act

The programs and initiatives in the Coronavirus Aid, Relief, and Economic Security (CARES) Act passed by Congress.

Download

Videos

OC Forum/UCI livestream

OC Forum and UCI hosted a livestream event on Orange County’s response to the coronavirus. It was held at the Cove, and we were happy to be able to facilitate the dissemination of much-needed information.

COVID-19 Research Funding Opportunities

BARDA

LINK TO INFO

First Available Due Date(s): 4/30/20
Expiration Date: 10/31/20

 

AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
AOI 8.3 COVID-19 Vaccine
AOI 9.2 COVID-19 Therapeutics
AOI 9.3 Immunomodulators or therapeutics targeting lung repair
AOI 9.5 Pre-exposure and post-exposure prophylaxis
AOI 10 Respiratory protective devices
AOI 11 Ventilators
AOI 17 Advanced Manufacturing Technologies
AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms

CDC

LINK TO INFO

First Available Due Date(s): 3/25/20
Expiration Date: 4/9/20

 

Area of Interest 1: Surveillance, natural history and household transmission of SARS CoV-2 DVD/RVB John Watson acq4@cdc.gov
Topic 1.1 Outcomes of SARS CoV-2 infections among different age groups in the US population
Topic 1.2 Natural history of SARS CoV-2 infections among special populations
Area of Interest 2: Diagnostics development and novel technology development and evaluation to improve diagnostic testing capabilities for COVID-19 detection DVD/RVB Steve Lindstrom sql5@cdc.gov
Area of Interest 3: Immune response and transmission dynamics for SARS CoV-2 DVD/RVB Natalie Thornburg nax3@cdc.gov
Topic 3.1 Antibody production against SARS CoV-2 for research reagents and potential therapeutics
Topic 3.2 Development of small animal models to define transmission and pathogenesis of SARS CoV-2
Topic 3.3 Identifying mechanism of possible immune mediated pathologies during COVID-19
Topic 3.4 Characterize seroprevalence of SARS CoV-2 antibodies in the US population
Area of Interst 4: Host infection dynamics for SARS CoV-2 DVD/RVB Suxiang Tong sot1@cdc.gov
Topic 4.1 Conduct a CRISPR screen for SARS CoV-2 to identify critical host cell components for viral infection.
Topic 4.2 Perform transcriptome analysis of patients samples with viral respiratory infection (COVID-19) to identify specific biomarkers of the disease
Topic 4.3 Investigate the transcriptional response to SARS CoV-2 infection in epithelial cells at the single cell level
Area of Interest 5: Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases ID/EPB Mark Thompson isq8@cdc.gov
Topic 5.1 Conduct prospective cohort studies to assess household transmission, transmissibility of infection, rates of infection and illness for key population groups, clinical epidemiology of disease, and characteristics of medically and non-medically attended COVID-19 cases
Area of Interest 1: Surveillance, natural history and household transmission of SARS CoV-2 DVD/RVB John Watson acq4@cdc.gov
Topic 1.1 Outcomes of SARS CoV-2 infections among different age groups in the US population
Topic 1.2 Natural history of SARS CoV-2 infections among special populations
Area of Interest 2: Diagnostics development and novel technology development and evaluation to improve diagnostic testing capabilities for COVID-19 detection DVD/RVB Steve Lindstrom sql5@cdc.gov
Area of Interest 3: Immune response and transmission dynamics for SARS CoV-2 DVD/RVB Natalie Thornburg nax3@cdc.gov
Topic 3.1 Antibody production against SARS CoV-2 for research reagents and potential therapeutics
Topic 3.2 Development of small animal models to define transmission and pathogenesis of SARS CoV-2
Topic 3.3 Identifying mechanism of possible immune mediated pathologies during COVID-19
Topic 3.4 Characterize seroprevalence of SARS CoV-2 antibodies in the US population
Area of Interst 4: Host infection dynamics for SARS CoV-2 DVD/RVB Suxiang Tong sot1@cdc.gov
Topic 4.1 Conduct a CRISPR screen for SARS CoV-2 to identify critical host cell components for viral infection.
Topic 4.2 Perform transcriptome analysis of patients samples with viral respiratory infection (COVID-19) to identify specific biomarkers of the disease
Topic 4.3 Investigate the transcriptional response to SARS CoV-2 infection in epithelial cells at the single cell level
Area of Interest 5: Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases ID/EPB Mark Thompson isq8@cdc.gov
Topic 5.1 Conduct prospective cohort studies to assess household transmission, transmissibility of infection, rates of infection and illness for key population groups, clinical epidemiology of disease, and characteristics of medically and non-medically attended COVID-19 cases

NIAID

LINK TO INFO

First Available Due Date(s): 4/9/20
Expiration Date: 6/30/21

Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases
Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases

NIH

LINK TO INFO

First Available Due Date(s): 2/6/20
Expiration Date: 2/6/21

In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:
Studies to identify optimal 2019-nCoV in vitro culture requirements and conditions;
Development of reagents and assays for virus characterization;
Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
Studies to identify viral epitopes critical for binding neutralization;
Studies to examine virus stability and persistence;
Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins;
Development of animal models of 2019-nCoV infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
Studies on the evolution and emergence of 2019-nCoV viruses including the identification of factors that affect viral host-range and virulence;
Virologic and serologic surveillance studies of the distribution and natural history of 2019-nCoV viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
Development of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV;
Development of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications;
Identification and evaluation of the innate, cellular and humoral immune responses to 2019-nCoV infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to 2019-nCoV and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
Development of 2019-nCoV vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.

NIH

LINK TO INFO

First Available Due Date(s): 6/29/20
Expiration Date: 6/30/20

Therapeutics projects supported by this FOA may include, but are not limited to, one or more of the following preclinical activities:
Lead optimization; medicinal chemistry; structure/activity relationships;
Synthesizing, purifying, and testing lead candidates for efficacy and toxicity in in vitro assays and preclinical in vivo model systems;
Performing preliminary pharmacokinetic (PK) and pharmacodynamics (PD) analyses on lead candidates;
Preclinical testing for efficacy and safety in animals;
Testing and validation of efficacy in in vitro or in vivo models (e.g., rodents, nonhuman primates);
Optimization of dose, dosing interval, and route of delivery in preclinical evaluation or in animal models;
Methods to modify existing drugs/therapeutics to improve economy of production, half-life in vivo, target affinity, neutralization potency, microbial clearance rates, or tissue accessibility; or to decrease adverse side effects of administration;
Evaluation of the potential for the emergence of drug/therapeutic resistance in model systems;
Assessing bioavailability and mechanism of action;
Process development for the manufacturing of a therapeutic, including QA/QC, methods for product recovery, characterization, purification, identity, stability etc.;
GLP or cGMP production to generate sufficient product to conduct pre-clinical and for future Phase I clinical studies; and
Performing required benchmarks for successful submission and review of an IND application by the FDA.

NIH

LINK TO INFO

First Available Due Date(s): 9/9/20
Expiration Date: 9/10/20

This FOA will support the further development and use of CC, CC derivatives with reproducible genomes and CC-RIX mice for immunologic investigation in areas of interest to NIAID. These research areas include, but are not limited to:
Studies of immune system development, regulation, and function during homeostasis and in response to vaccine adjuvants and/or antigenic challenge (e.g. infectious pathogens, vaccines, model antigens)
Identification of novel immune regulatory genes and their mechanisms of action
Development, generation, and maintenance of innate and adaptive immunity during homeostasis or in response to infections or vaccinations at all stages of life, starting with in utero development and including early life through aging
Characterization of host genetics, microbial flora, and immune regulatory outcomes across the lifespan
Studies of regulatory mechanisms of environmental exposure and risk factors that promote atopic or asthma diathesis
Development and characterization of new models for asthma and allergic disease phenotypes and endotypes
Identification of genetic determinants underlying the differences in sensitivity to allergens, and response to allergen‐specific immunotherapy
Identification of genetic contributions to routes of allergic sensitization
Development and characterization of new models for autoimmune diseases
Identification of genetic and immune system contribution to autoimmune diseases
Characterization of the genetic basis of primary immunodeficiency diseases
Development and characterization of new models for cell/organ/tissue rejection or tolerance
Studies of immune system development, regulation, and function in response to alloantigens
Studies of infectious disease pathogenesis with the ultimate goal of identifying:
Novel targets/antigens for vaccine development
Novel targets for therapeutics development
Infectious disease-related biomarkers, including:
– Biomarkers to predict susceptibility to infection and/or diagnose an infectious disease;
– Biomarkers to diagnose individuals infected with pathogens or who have been exposed to toxins;
– Biomarkers to predict or monitor a subject’s response to therapeutics or vaccinations;
– Biomarkers from natural history studies that could be used to assess disease progression in acute and chronic infectious diseases.

NIH

LINK TO INFO

First Available Due Date(s): 3/19/20
Expiration Date: 3/31/21

In order to rapidly improve our understanding of the risks, prevalence, and available control measures for 2019-nCoV in substance using or HIV-affected populations, NIDA is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:
Research to determine whether substance use (especially smoking tobacco or marijuana, vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19.
Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.
Research to understand system-level responses to COVID-19 prevention and risk mitigation in secure settings such as prisons and jails, with a particular emphasis on detainees with substance use disorder (SUD). For example:
Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders
Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.
Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD); in particular those with nicotine, marijuana, opioid, and methamphetamine use disorders.
Research to understand how the respiratory effects of COVID-19 influences the rate of opioid overdoses both in pain patients as well as patients with an opioid use disorders and also to assess how it influences the outcomes for naloxone interventions for overdose reversal
Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.
Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.
Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.
Research to understand and mitigate the impact of COVID-19 in methadone treatment programs and syringe exchange services.
Research on how potential overcrowding of emergency departments and health services will impact the treatment of opioid overdoses and of opioid use disorder
Research using ongoing studies to understand the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment.

NIH

LINK TO INFO

First Available Due Date(s): 3/17/20
Expiration Date: 10/6/20

To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations.
Possible research interests include but are not limited to the following:
Host factors, including the microbiome or existing cardiac, respiratory, or hematologic conditions, that predispose persons to acquire SARS-CoV-2 or to develop severe COVID-19 disease, or that confer resistance to severe disease as in infants and young children
Manifestations, complications, and long-term consequences of SARS-CoV-2 infection, including identification of predictive biomarkers derived from imaging, clinical data, and biospecimens collected across organ systems
Time course and features of virus-host interactions, including the impact of SARS-CoV-2 infection on innate and adaptive immune responses
Prevalence and mechanisms of lung and cardiac injury with SARS-CoV-2 infection
Host factors and biological pathways that impact recovery and repair of the cardiopulmonary and vascular systems after SARS-CoV-2 infection
Development of animal or in vitro models of SARS-CoV-2 infection suitable for pathogenesis and therapeutic studies or transfusion transmission experiments such as, but not limited to, macaque and ACE-2 receptor murine models
Use of artificial intelligence or machine learning approaches to understand the biological pathways of COVID-19 disease, its comorbidities, and potential prevention strategies
Prevalence of RNAemia in symptomatic and asymptomatic people found to test positive for SARS-CoV-2 using respiratory tract samples
Dynamics of SARS-CoV-2 viremia and antibody response, and implications on screening and diagnostic assay development
Development of GMP quality hyper immune globulin from convalescent plasma collected from patients who have recovered from documented SARS-CoV-2 infection
Development and testing of strategies at the healthcare system level to address barriers and facilitators in the treatment of high-risk populations, particularly rural residents and underserved individuals

NIH

LINK TO INFO

First Available Due Date(s): open
Expiration Date: 1/25/22

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.
Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

NIH

LINK TO INFO

First Available Due Date(s): 5/13/20
Expiration Date: 1/14/23

This Funding Opportunity Announcement (FOA) supports applications for conducting investigator-initiated, milestone-driven, long-term (6 or 7 year) incrementally funded clinical trials (all phases) and associated mechanistic studies as indicated in NIH Institute/Center (IC) specific areas.
NIH defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

NIHR

LINK TO INFO

First Available Due Date(s): open
Expiration Date: open

This scheme provides travel and subsistence funding to support delivery of technical expertise in the global response to Covid-19.

NSF

LINK TO INFO

First Available Due Date(s): open
Expiration Date: open

Before submitting a RAPID proposal or supplemental funding request in response to this DCL, investigators must first contact one of the cognizant OAC program officers listed

DOD

LINK TO INFO

First Available Due Date(s): 4/15/20
Expiration Date: 4/30/20

MTEC believes that an emphasis will be placed on technologies that can be deployed as soon as possible but no later than 31 December 2020. In support of this, MTEC has identified the following potential areas of interest:
Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.
Disease predictive modeling that provides early warning through data capture from several different streams of data to include social media and artificial intelligence (AI) parameter decision tools that would provide actionable information to medical service providers and command structures.
Patient monitoring, tracking, and management system for in-home or non-hospital environment patient tele-health services to include interface into the Cerner electronic health record.

University of Texas

LINK TO INFO

University of Texas link to Covid-19 related funding opportunities